SCHEMBL6741072

SCHEMBL6741072

O=C(CNC(=O)OCc1ccccc1)CNC(=O)OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HTT P42858 1/20 0.61
ALDH1A1 P00352 3/20 0.58
CTSL P07711 1/20 0.57
CTSB P07858 1/20 0.57
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
TGM2 P21980 1/20 0.54
KDM1A O60341 1/20 0.53
RCOR1 Q9UKL0 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5172945 0.91 LMNA (0.59) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL13644307 0.90 LMNA (0.58) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL5217165 0.90 SMN1; SMN2 (0.58) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL126974 0.89 HTT (0.66) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL11783251 0.89 HTT (0.66) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL7285795 0.89 HTT (0.57) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL15561304 0.89 HTT (0.66) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL7907133 0.88 SYK (0.62) LMNASMN1; SMN2HTTALDH1A1CTSL
Hydrochloric Acid SCHEMBL8688569 0.87 HTT (0.64) LMNASMN1; SMN2HTTALDH1A1CTSL
SCHEMBL10081124 0.87 LMNA (0.63) LMNASMN1; SMN2HTTALDH1A1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135234-B2 Effective aminoglycoside antibiotic for multidrug-resistant bacteria MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2021-10-05 US disclosed
CN-108026133-B Novel aminoglycoside antibiotics effective against multidrug resistant bacteria 公益财团法人微生物化学研究会 2021-05-07 CN disclosed
US-20200155582-A1 EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2020-05-21 US disclosed
US-10617704-B2 Effective aminoglycoside antibiotic for multidrug-resistant bacteria MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2020-04-14 US disclosed
US-10576094-B2 2020-03-03 US disclosed
EP-3498723-A1 NEW EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA Microbial Chemistry Research Foundation (JP) 2019-06-19 EP disclosed
US-20180214470-A1 NEW EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) 2018-08-02 US disclosed
EP-3330275-A1 NOVEL AMINOGLYCOSIDE ANTIBIOTIC EFFECTIVE AGAINST MULTIDRUG-RESISTANT BACTERIA Microbial Chemistry Research Foundation (JP) 2018-06-06 EP disclosed
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives G. D. SEARLE & CO. (US) 2004-07-01 US disclosed
US-6689754-B1 PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS G. D. SEARLE & CO. 2004-02-10 US disclosed
EP-1070060-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. Searle & Co. (US) 2001-01-24 EP disclosed
WO-1999052896-A1 HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS G.D. SEARLE & CO. (US) 1999-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127477-A1 Heterocyclic glycyl beta-alanine derivatives ITGB3, ITGAL, ITGB1 LMNA 972/4885SMN1; SMN2 811/4885HTT 4453/4885
US-20180214470-A1 NEW EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA ABCC1, SLC11A2, RPN2 LMNA 2396/4885SMN1; SMN2 3376/4885HTT 3698/4885
US-20200155582-A1 EFFECTIVE AMINOGLYCOSIDE ANTIBIOTIC FOR MULTIDRUG-RESISTANT BACTERIA ABCC1, ABCB11, SLC11A2 LMNA 2398/4885SMN1; SMN2 3037/4885HTT 3355/4885
US-10617704-B2 Effective aminoglycoside antibiotic for multidrug-resistant bacteria ABCC1, ABCB11, SLC11A2 LMNA 2398/4885SMN1; SMN2 3037/4885HTT 3355/4885
US-10576094-B2 ALPI, REN, GMDS LMNA 2645/4885SMN1; SMN2 2487/4885HTT 3770/4885
US-11135234-B2 Effective aminoglycoside antibiotic for multidrug-resistant bacteria ABCC1, ABCB11, SLC11A2 LMNA 2398/4885SMN1; SMN2 3037/4885HTT 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.